Sector News

Oxford regenerative medicine spinout brings on GlaxoSmithKline drug hunter as CSO

September 10, 2018
Life sciences

The University of Oxford’s regenerative drug discovery spinout OxStem Limited has appointed Georg Terstappen as chief scientific officer, to lead development work across its portfolio of six programs that aim to stimulate progenitor and stem cell repair mechanisms within the body.

Most recently, Terstappen served as head of platform technologies and science at GlaxoSmithKline’s R&D center in Shanghai, helping to oversee preclinical drug development. Before that, he headed up discovery biology at AbbVie’s Ludwigshafen, Germany location.

He has also held positions at Bayer, GlaxoWellcome and Siena Biotech, where he was co-founder and CSO.

In addition, Terstappen has held positions at the European Federation of Pharmaceutical Industries and Associations, including vice-chair of the organization’s innovative medicines strategy group, under its public-private Innovative Medicines Initiative. He is also a founding member and co-chair of the IMI’s strategic governing group for neurodegeneration.

OxStem itself acts as a parent holding company, overseeing and funding development of small molecule drugs at a series of subsidiaries, each focused on different therapeutic needs and organ systems. Its current roster includes OxStem Neuro, OxStem Oncology, OxStem Ocular and OxStem Cardio, all of which are in the discovery stage.

Two more branches are being planned: OxStem Immuno, in wound healing and inflammation, and OxStem Beta, targeting the regeneration of insulin-producing beta cells.

Its Neuro outfit is aiming to identify a new class of drugs that stimulate de novo neuron production from neural stem cells to counteract degenerative diseases such as Alzheimer’s.

Similarly, OxStem Cardio hopes to stimulate resident cardiac precursor cells to increase muscle regeneration and improve function following a heart attack, while OxStem Ocular looks to stimulate photoreceptor cell production within the retina.

OxStem Oncology, meanwhile, is looking to develop treatments for a wide range of cancer types, and the “cancer stem-like cells” that can persist after therapy. The company hopes to develop drugs that force those cells to differentiate into more benign states.

By Conor Hale

Source: Fierce Biotech

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach